The presence of transient PD-L1+/CXCL9+/CXCL10+ myeloid clusters at sites that later develop tumors suggests that immune organization itself may serve as an early biomarker—and potentially a therapeutic target—for cancer interception. Here, CXCL9 is linked to cancer.